Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on th...

Descripción completa

Detalles Bibliográficos
Autores principales: McMullen, Michelle, Karakasis, Katherine, Madariaga, Ainhoa, Oza, Amit M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352566/
https://www.ncbi.nlm.nih.gov/pubmed/32560564
http://dx.doi.org/10.3390/cancers12061607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352566/
https://www.ncbi.nlm.nih.gov/pubmed/32560564
http://dx.doi.org/10.3390/cancers12061607

Ejemplares similares